Background-Although significant undersizing often results in incomplete stent apposition or underexpansion, the possible impact of oversized stent implantation on arterial wall injury has not been systematically investigated with drug-eluting stents. The aim of this study was to investigate the impact of stent oversizing on acute and long-term outcomes after drugeluting stents implantation in de novo coronary lesions. Methods and Results-Serial (baseline and 6-12 months) coronary angiography and intravascular ultrasound were performed in 2931 lesions treated with drug-eluting stents (355 sirolimus, 846 paclitaxel, 1387 zotarolimus, and 343 everolimus). The percentage of stent oversizing to angiographic reference vessel diameter (RVD) was calculated as (nominal stent diameter-RVD)/RVD×100 (%). Clinical outcomes, including target lesion revascularization and stent thrombosis, were followed for 1 year. Overall, smaller preintervention RVD was associated with higher percentage of stent oversizing (P<0.001). The significant oversizing group underwent less post-dilatation (P=0.002) but achieved greater stent expansion (P<0.001) and less incomplete stent apposition (P<0.001) without increase of edge dissection after procedure. When stratified by vessel size and stent oversizing, progressive decreases of restenosis (P=0.002) and target lesion revascularization rates (P=0.007) were found in favor of larger vessel size and oversized stents. Stent thrombosis was observed the most in small RVD with low percentage of stent oversizing group among the subgroups (P=0.040). Conclusions-The positive impact of stent oversizing was documented on procedural and clinical outcomes. In particular, small vessels treated with smaller stents were associated with greater adverse events, suggesting that aggressive selection of larger stents, with appropriate attention to edge effects, may optimize long-term outcomes, even in drug-eluting stents implantation. (Circ Cardiovasc Interv. 2017;10:e004795.
I
n the bare-metal stent era, numerous studies have shown a strong association between small final stent dimensions at post-deployment and in-stent restenosis at follow-up, [1] [2] [3] which led to the so-called bigger-is-better strategy for bare-metal stent optimization. After the introduction of drug-eluting stents (DES), several studies have consistently demonstrated that DES have considerably lower optimal thresholds of final stent dimensions to predict subsequent restenosis because of significant suppression of neointimal proliferation within the stent. 4 Combined with the fact that some early DES trials demonstrated a relatively high incidence of restenosis at the stent edge segment, the stenting procedure in the DES era has changed from the aggressive to the adequate strategy. In clinical settings, however, final stent expansion often fails to meet expected stent dimensions after DES implantation. 5 Furthermore, there is compelling clinical evidence that significant stent undersizing of DES often ends up with suboptimal results, particularly stent underexpansion, which can lead to adverse clinical events, such as restenosis and stent thrombosis. [6] [7] [8] Therefore, selection of proper device size relative to the target vessel may be considered as important as postdeployment optimization strategy. Recently, the importance of accurate device sizing has also gained further attention due to the introduction of bioresorbable scaffold technology into the clinical arena because polymer-based devices cannot be overly dilated after implantation.
At the other end of this spectrum, however, potential effects of oversized stent implantation on arterial wall injury and vascular response have not been systematically evaluated. Thus, the aim of this study was to investigate the impact of stent oversizing on acute and long-term outcomes after DES implantation in de novo coronary lesions. Impact of Stent Size Selection on Outcomes of DES
Methods

Study Population
The original study data were pooled at both patient and lesion levels from 14 10 19 (Table I in the Data Supplement). The study designs and primary results have been previously reported. These trials were conducted in accordance with virtually identical inclusion and exclusion criteria. In brief, they were prospective, multicenter, randomized, or nonrandomized trials to evaluate the safety and efficacy of DES in stable or unstable angina patients with 1 or 2 de novo lesions in native coronary arteries with a diameter of 2.25 to 4.25 mm. The major exclusion criteria of these trials included acute myocardial infarction, stroke, impaired left ventricular function (ejection fraction 30%), ostial or left main lesions, and previously treated lesions. In these trials, the intravascular ultrasound (IVUS) cohorts were configured with volumetric IVUS studies prescheduled at baseline and midterm (6-12 months) follow-up. From these IVUS cohorts, patients with analyzable quantitative coronary angiography (QCA) data, who had undergone successful treatment with Cypher sirolimus-eluting stents, Taxus paclitaxel-eluting stents, Endeavor/Resolute/ZoMaxx zotarolimus-eluting stents, or Xience V everolimus-eluting stents, were enrolled in this analysis. Clinical outcomes, including target lesion revascularization (TLR) and stent thrombosis, were followed for 1 year. TLR was defined as any repeat percutaneous coronary intervention for the target lesion or bypass surgery of the target vessel, and stent thrombosis included definite and probable events according to Academic Research Consortium definitions. 20 The study protocol for each clinical trial was approved by the institutional review board at each participating site, and eligible patients signed written informed consent before the interventional procedure.
QCA Analysis
Coronary angiograms performed at baseline and follow-up were reviewed by an independent angiographic core laboratory in each trial (Cardiovascular Research Foundation, New York, NY, or Beth Israel Deaconess Medical Center, Boston, MA) using a standard manner. Reference vessel diameter (RVD) and minimum lumen diameter were measured in the target segment. Percent diameter stenosis (%DS) was calculated as (1−minimum lumen diameter/RVD)×100. In the DES trials included in this analysis, angiographic end points were standard binary restenosis (%DS ≥50%) and late loss (minimum lumen diameter at post-intervention−minimum lumen diameter at follow-up) by QCA.
IVUS Analysis
IVUS was performed in a standard fashion using automated 0.5 mm/s pullback with a commercially available imaging system (40-MHz IVUS catheter, Boston Scientific Corp, Natick, MA; or 20-MHz IVUS catheter, Volcano Corp, San Diego, CA) at baseline and followup. IVUS analysis was conducted in an independent core laboratory (Stanford Cardiovascular Core Analysis Laboratory, Stanford, CA), and analysts were blinded to clinical characteristics, angiographic information, and randomization assignments. Volumetric measurements were performed using validated software (echoPlaque; Indec Systems, Santa Clara, CA). Volume index (VI, volume/length, mm 3 / mm) was calculated for the vessel, lumen, plaque, stent, and neointima in the stented segment. Vessel, lumen, and plaque VI were also obtained for the stent margins, 5 mm proximal and distal to the stent. Percent neointimal volume was calculated as neointimal volume divided by stent volume (%). Cross-sectional narrowing (%) was defined as neointimal area divided by stent area. Incomplete stent apposition (ISA) was defined as ≥1 stent strut clearly separated from the vessel wall, with evidence of blood speckles behind the strut in a vessel segment not associated with any side branches. Late-acquired ISA was defined as newly developed ISA at follow-up in the segment where struts were completely apposed to the vessel wall at baseline. Any edge dissection detected as a fissure or separation within intima or plaque was counted. Stent expansion at baseline was calculated as minimum stent area divided by the average of proximal and distal reference lumen areas.
WHAT IS KNOWN
• Final stent expansion often fails to meet expected stent dimensions after drug-eluting stent implantation, and suboptimal stent expansion can lead to adverse clinical events.
• Although selection of drug-eluting stent size relative to the target vessel is considered as important as postdeployment optimization strategy, the impact of oversized stent implantation on acute and long-term outcomes remains unclear.
WHAT THE STUDY ADDS
• Aggressive selection of larger drug-eluting stent, with appropriate attention to edge effects under intravascular ultrasound guidance, may result in greater stent expansion, without significant increase in residual edge dissection.
• Furthermore, long-term adverse events may be reduced by stent oversizing, especially in small vessels, without accelerated restenosis or plaque progression at the stent edge. Impact of Stent Size Selection on Outcomes of DES
Percent Stent Oversizing
For evaluating the degree of stent oversizing relative to the vessel size, the percentage of stent oversizing (%SO) against angiographic preintervention RVD was calculated as (nominal stent diameter−RVD)/ RVD×100 (%). In lesions with >1 stents overlapped, average nominal stent diameter was applied for the calculation. Because preintervention RVD itself is known as one of the determinants of clinical outcomes, possible impact of stent oversizing was further investigated by stratifying the lesions by vessel size (ie, small versus large RVD lesions).
Statistical Analysis
Statistical analysis was performed using JMP 10.0 (SAS Institute, Cary, NC). Categorical variables are presented as numbers and percentages and were compared using χ 2 test or Fisher exact test. All pairwise comparisons among the 4 stratified groups were conducted using χ 2 test with a Bonferroni correction. Continuous variables are presented as mean±SD. Comparisons of the mean of continuous variables among the 4 stratified groups were done with the general F test for ANOVA with a post hoc comparison using the Tukey honestly significant difference test. When the homoscedasticity was not verified by the Levene test, the mean of continuous variables was compared using Welch ANOVA with a post hoc comparison using Welch t test with a Bonferroni correction. Correlation between preintervention RVD and %SO was examined using a polynomial regression model. A nominal P<0.05 was considered statistically significant. Forward stepwise multivariate logistic regression models were used to determine independent predictors of TLR and stent thrombosis. Major clinical, procedural, angiographic, and IVUS variables with P<0.05 in univariate models were included simultaneously in multivariate models. For predictors of TLR, because the incidence of TLR decreased stepwise in favor of larger vessel size and oversized stents, the 4 groups were scored as 1 to 4 to be included in these models. For predictors of stent thrombosis, the small RVD with low %SO was used as a binary parameter because of its remarkably high incidence of stent thrombosis compared with the other 3 groups. The variables representing vessel, lumen, and stent dimensions were excluded because of their significant correlations with 4 stratified subgroups by RVD and %SO. In addition, number of stents, rate of multiple stent implantations, and lesion length were excluded because these variables were strongly correlated with total stent length.
Results
Study Population and Clinical Characteristics
A total of 2931 lesions in 2808 patients treated with sirolimus-eluting stents (n=335), paclitaxel-eluting stents (n=846), zotarolimus-eluting stents (n=1387 [Endeavor, n=853; Resolute, n=211; and ZoMaxx, n=323]), and everolimus-eluting stents (n=343) were enrolled in the present study. Patient characteristics in the overall population are shown in Table 1 . The mean age was 62.8 years old, 71.4% of patients were men, and 41% presented with unstable angina.
Relationship Between RVD and %SO, and Stratification Into 4 Groups
Overall, smaller preintervention RVD significantly correlated with higher %SO (r 2 =0.452; P<0.001; Figure 1 ). Significant stent oversizing (high %SO, defined as %SO ≥10%) was found in 82% of the small RVD (<2.75 mm) group and 33% of the larger RVD (≥2.75 mm) group. For further analysis, lesions were stratified into 4 groups by vessel size (RVD ≥ or < 2.75 mm) and stent oversizing (%SO ≥ or < 10%). Among the 4 groups, DES type did not differ (P=0.525) while there were several differences in lesion and other procedural characteristics (Table 2 ). Of note, the lesions with low %SO included more type B2/C lesions and underwent more overall and upsizing post-dilatations. The total number of stents used and total stent length were not significantly different among the 4 groups, whereas the use of multiple stents was most frequent in the small RVD with low %SO group ( Table 2) .
QCA Results
QCA results were summarized in Table 3 . Despite the similar %DS at pre-intervention among the 4 groups, %DS at postintervention was significantly higher in lesions with low %SO compared with those with high %SO. At follow-up, %DS was also numerically (small RVD groups) or significantly (large RVD groups) higher in lesions with low %SO compared with those with high %SO. The rate of binary restenosis at follow-up was significantly lower in lesions with large RVD than those with small RVD and the lowest in the large RVD with high %SO group (Figure 2) . With respect to edge effect, 
IVUS Results
At baseline, progressive increases of lumen and stent VI and minimum lumen area (MLA) were in favor of larger vessel size and oversized stents ( Table 4 ). The high %SO groups achieved greater stent expansion (P<0.001) and less ISA (P<0.001), without a significant increase of edge dissection after implantation (Figure 3 ). At follow-up, in lesions with small RVD, the greater stent expansion achieved at baseline compensated the slightly greater in-stent neointimal proliferation (P<0.001 for neointimal VI and percent neointimal volume; P=0.042 for %max cross-sectional narrowing) observed in the high %SO group, resulting in significantly larger lumen dimensions at follow-up (P=0.002 for lumen VI; P=0.012 for MLA) compared with the low %SO group. In lesions with large RVD, the greater stent expansion at baseline in the high %SO group directly translated into the larger lumen dimensions at follow-up (P<0.001 for both lumen VI and MLA) because of the similar neointimal proliferation observed between the high versus low %SO groups. With respect to possible edge effect of stent oversizing, no significant difference was observed in reference segment IVUS parameter changes (Δ from baseline to follow-up) in both small and large RVD lesions, indicating comparable plaque 
Clinical Outcomes in 1 Year
In this analysis, the data of clinical outcomes were obtained in 2869 vessels (97.9%) at 1-year follow-up. Progressive decrease of TLR rate was found in favor of larger vessel size and oversized stents at 1 year after implantation (Figure 4) . The incidence of definite/probable stent thrombosis was significantly higher in the small RVD with low %SO group than in the other 3 groups. The multivariate model using variables with P<0.05 in univariate models determined 4 independent predictors of TLR: diabetes mellitus, prior bypass surgery, total stent length, and stratified groups by RVD and %SO (Table III in the Data  Supplement) . For stent thrombosis, the multivariate model determined 3 independent predictors: diabetes mellitus, current smoking, and lesions with small RVD and low %SO (Table IV in the Data Supplement). In terms of effect-modification by age-group or sex, no statistically significant interactions were found to the TLR rate among the 4 groups or to the rate of stent In-stent angiographic binary restenosis at follow-up was significantly lower in lesions with large reference vessel diameter (RVD) than those with small RVD and was lowest in the large RVD with high %stent oversizing (%SO) group. In contrast, no significant difference was observed in binary restenosis localized at the adjacent reference (stent edge) segment. 
Effect of Very High Oversizing
The additional analyses were conducted with further stratification into 3 groups: low (%SO <10%), high (10%-30%), and very high (>30%) oversizing to explore the upper limit of stent oversizing (Table VI in the Data Supplement). In small vessels, the very high oversizing achieved the greatest stent area at postprocedure, which resulted in the largest lumen VI and MLA at follow-up, despite the greatest neointimal proliferation. Importantly, the very high oversizing did not lead to increased edge dissections at post-procedure compared with the low and high oversizing groups. As a result, the vessels with very high %SO tended to have the lowest incidence of TLR. In large vessels, however, there were only 4 cases in the very high oversizing (%SO >30%) category. Although statistical analysis would not be feasible, these 4 cases had no edge dissection at post-procedure and no TLR or stent thrombosis at follow-up.
Discussion
The main findings of this analysis are as follows: (1) Overall, stent size selection was affected by the reference vessel dimension; (2) Lesions with significant stent oversizing underwent less post-dilatation but achieved greater stent expansion and less ISA, without increasing edge dissection after procedure; (3) When stratified by vessel size and stent oversizing, progressive decreases of angiographic binary restenosis and TLR rates were found in favor of larger vessel size and oversized stents, with no difference in restenosis or plaque progression at the stent edge between lesions with and without stent oversizing; and (4) Stent thrombosis was observed the most in small vessels without stent oversizing among the subgroups. . Clinical outcomes at 1 year. Progressive decrease of target lesion revascularization (TLR) rate was found in favor of larger vessel size and oversized stents in 1 year after implantation. The incidence of definite/probable stent thrombosis was significantly higher in the small reference vessel diameter (RVD) with low %stent oversizing (%SO) group than in the other 3 groups. Impact of Stent Size Selection on Outcomes of DES
Stent Size Selection and Final Stent Expansion
There have been few studies systemically investigating the impact of stent size selection on final stent expansion after coronary stent implantation. In the present study, the selected stent size relative to RVD varied depending on the vessel size.
In small vessels, a relatively larger stent might have been intentionally selected to achieve sufficient stent expansion. In large vessels, however, the operators tended to select a relatively smaller stent because adequate stent expansion might have been considered easier to achieve, even without aggressive stent dilation. At post-intervention, the lesions with significant stent oversizing achieved greater stent expansion and less ISA, without increase of edge dissection, despite the less frequent upsizing post-dilatation, compared with those without stent oversizing. The current results may suggest that aggressive selection of a larger stent might be an effective option to obtain better stent expansion while avoiding aggressive post-dilatation. Of note, however, there may be some lesions in which the oversized stent implantation is considered inappropriate because of increased risks of coronary perforation, such as chronic total occlusion, 21, 22 severe calcification, [21] [22] [23] or eccentric lesions. 21, 23 Further investigation involving detailed assessment of lesion or plaque characteristics would be warranted to confirm this hypothesis.
Vascular Response to Stent Oversizing at Adjacent Edge Segment
Although oversized stents can potentially cause vascular injury at the adjacent edge segment, 24 the current study demonstrated relatively low and comparable incidences of poststent edge dissection across the 4 subgroups. This may be, in part, because the operators were allowed to use IVUS for the guidance of stent implantation and optimization in this study population. Final IVUS assessment at post-procedure can also underestimate the occurrence of initial edge dissection if additional bailout stent implantation is performed in response to the postdeployment IVUS observation. In the present study, however, the total number of stents implanted per lesion did not differ between the lesions with and without stent oversizing. In addition, multiple stent implantation was not more frequent in lesions with stent oversizing, suggesting that aggressive selection of a larger stent may not necessarily lead to a significant increase in residual edge dissection if appropriate attention to edge effect is given.
A previous study evaluating first-generation sirolimuseluting stents also reported that edge restenosis could be induced by vessel overstretching because of stent overexpansion. 25 In the present study with various types of DES including newer generation stents, however, neither increased edge restenosis nor significant plaque progression in the adjacent reference segment was observed in the oversizing groups compared with the nonoversizing groups.
Effect of Stent Oversizing on Neointimal Proliferation
Although the bigger-is-better strategy has been the widely accepted principle in the bare-metal stent era, it has also been reported that overly aggressive stent deployment can lead to increased neointimal proliferation, 26, 27 which is likely related to vessel injury caused by overstretching. [27] [28] [29] Although one study reported that arterial injury as assessed by the balloon-toartery ratio was not associated with the amount of neointimal hyperplasia in sirolimus-eluting stents and paclitaxel-eluting stents, 30 the exact impact of stent oversizing has not been well investigated in DES. In the present study, stent oversizing resulted in no significant increase of neointimal proliferation in large target vessels. However, in small vessels, stent oversizing was associated with a slight but significantly greater amount of neointima, suggesting that small target vessels might be more susceptible to overstretch injury, which could promote neointimal proliferation even after DES implantation. Overall, however, current DES technology seems to offer a sufficiently potent antiproliferative effect so that the disadvantage of vessel injury was counterbalanced by the advantage of larger final stent dimensions achieved with oversized stents, resulting in significantly larger follow-up lumen in the oversizing group of the present study.
Long-Term Outcomes
It is well recognized that vessel size is one of the strongest determinants of long-term outcomes after coronary stenting. Specifically, smaller target vessel dimensions have been reported as an independent predictor of restenosis and repeat revascularization even after DES implantation. 31 In addition, it has also been reported that final stent expansion is related to subsequent adverse clinical events, including restenosis and stent thrombosis. 6, 32, 33 However, it remained unclear whether optimal selection of DES size itself could contribute to the improvement of long-term clinical outcomes. In the present study, the incidences of angiographic restenosis, TLR, and stent thrombosis were all highest in small vessels without stent oversizing, and the results suggest possible benefits of oversized stent selection, especially in small vessels. Although the limited number of patients in the very high oversizing group in large vessels precludes direct comparison of benefits and limitations of higher oversizing, small vessels seem to tolerate higher oversizing well, demonstrating no increased complications in this analysis. In the trials included in this analysis, operators were allowed to use IVUS information to guide stent deployment and optimization, which may, in part, account for the favorable results.
During the past few years, bioresorbable scaffold technology has evolved, 34, 35 and its advent has refocused attention to accurate device size selection because overdilation of undersized biodegradable stents can damage the polymer struts. Conversely, a recent study also reported that implantation of an oversized bioresorbable scaffold in a relatively small vessel appeared to be associated with a higher 1-year adverse event rate, 36 which is inconsistent with our results with metallic DES. It is reasonable that proper implantation methods may vary according to the design and material of device. Thus, the appropriate selection of device size and deployment strategy for each type of device should be individually established to derive the best clinical benefits from specific devices.
Study Limitations
There were several limitations in this study. First, this is a retrospective study from pooled analyses, raising a possibility of Impact of Stent Size Selection on Outcomes of DES selection bias. Also, the data collected from a large number of participating sites may have enhanced the generalizability of the current results but at the expense of possibly increased variability in outcomes. Second, there is an imbalance of sample size among the 4 stratified groups. Third, detailed medical therapy information was not available in all the investigated patients. Fourth, the lesions' composition can be an important variable affecting the outcome. However, the present study is a pooled data analysis of clinical DES trials with common exclusion criteria, such as severely calcified lesions, thrombus-containing lesions, ST-segment-elevation myocardial infarction, etc. Also, although preprocedural IVUS imaging would be required for accurate lesion composition assessment, most trial protocols mandated IVUS interrogation only at post-intervention and follow-up. Fifth, detailed patientlevel data on peri-procedural complications, such as slow/no reflow phenomenon, and anticoagulant/antiplatelet therapy, were not fully available in some of the trials. As supportive information about peri-procedural complications, however, there was no significant difference in the rate of myocardial infarction on the date of percutaneous coronary intervention among the 4 stratified groups (P=0.168). Sixth, preprocedural IVUS imaging could provide more accurate reference diameter measurements that would allow more aggressive oversizing. Practically, however, the use of preprocedural IVUS for device sizing in every stent case would not be warranted in most countries where angiography-guided percutaneous coronary intervention is still dominantly performed in the majority of patients. The potential benefit of further aggressive oversizing with IVUS guidance certainly represents a clinically important question, especially in complex lesions/patients or with particular devices, such as bioresorbable scaffolds, and therefore would warrant further systematic investigations. Finally, possible differences among DES types could not be fully evaluated because of insufficient statistical power when each group was further divided into DES subgroups.
Conclusions
In this pooled data analysis, the positive impact of stent oversizing was documented with respect to procedural and clinical outcomes. Long-term adverse events appeared to be related to not only the vessel size itself but also the selection of a stent larger than the vessel size. In particular, small vessels treated with a smaller stent were associated with greater adverse events, suggesting that aggressive selection of larger stents, with appropriate attention to edge effects, may optimize longterm outcomes, even in DES implantation.
